SOUTH SAN FRANCISCO, Jun 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE)CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-022-03 clinical trial, which demonstrate that the Cellworks Singula(TM) Therapy Response Index (TRI) is strongly predictive of Overall Survival (OS) and Disease-Free Survival (DFS) for Glioblastoma (GBM) patients. The study also validates that Singula(TM) TRI provides predictive value to physicians beyond standard clinical factors, such as patient age, patient gender and physician-prescribed treatment.